Tremfya (also known by its generic name guselkumab) is a biologic medication that was approved by the FDA in July 2017 for the treatment of moderate-to-severe plaque psoriasis in adults. In July 2020, the FDA also approved Tremfya to treat adults with active psoriatic arthritis. Tremfya was approved in September 2025 to treat children aged 6 or older with moderate to severe plaque psoriasis or with active psoriatic arthritis (PsA).
Tremfya is given by injection under the skin at week 0 (the first week of treatment) and week 4, and then every 8 weeks afterwards.
To learn more, please visit the Tremfya website.
